

ERK5 kinase activity is dispensable for cellular immune response and proliferation

Emme C. K. Lin^{a,1}, Christopher M. Amantea^a, Tyzoon K. Nomanbhoy^a, Helge Weissig^a, Junichi Ishiyama^b, Yi Hu^a, Shyama Sidique^a, Bei Li^a, John W. Kozarich^a, and Jonathan S. Rosenblum^{a,1}

^aActivX Biosciences, Inc., La Jolla, CA 92037; and ^bWatarase Research Center, Kyorin Pharmaceutical Co., Ltd., Tochigi 329-0114, Japan

Edited by Stephen J. Benkovic, The Pennsylvania State University, University Park, PA, and approved August 23, 2016 (received for review June 6, 2016)

Unlike other members of the MAPK family, ERK5 contains a large C-terminal domain with transcriptional activation capability in addition to an N-terminal canonical kinase domain. Genetic deletion of ERK5 is embryonic lethal, and tissue-restricted deletions have profound effects on erythroid development, cardiac function, and neurogenesis. In addition, depletion of ERK5 is antiinflammatory and antitumorigenic. Small molecule inhibition of ERK5 has been shown to have promising activity in cell and animal models of inflammation and oncology. Here we report the synthesis and biological characterization of potent, selective ERK5 inhibitors. In contrast to both genetic depletion/deletion of ERK5 and inhibition with previously reported compounds, inhibition of the kinase with the most selective of the new inhibitors had no antiinflammatory or antiproliferative activity. The source of efficacy in previously reported ERK5 inhibitors is shown to be off-target activity on bromodomains, conserved protein modules involved in recognition of acetyl-lysine residues during transcriptional processes. It is likely that phenotypes reported from genetic deletion or depletion of ERK5 arise from removal of a noncatalytic function of ERK5. The newly reported inhibitors should be useful in determining which of the many reported phenotypes are due to kinase activity and delineate which can be pharmacologically targeted.

ERK5 | bromodomain | inflammation | proliferation | kinase

Extracellular signal-regulated kinase 5 (ERK5, BMK1) is a member of the mitogen-activated protein kinase (MAPK) family, which includes ERK1/2, JNK1/2/3, and $p38\alpha/\beta/\delta/\gamma$ (1). However, unlike the other MAPK members, ERK5 contains a unique 400-amino-acid C-terminal domain in addition to the kinase domain. Through the MAPK signaling cascade, mitogenactivated protein kinase kinase 5 (MEK5) activates ERK5 by phosphorylating the TEY motif in the N-terminal activation loop (2). This event unlocks the N- and C-terminal halves, allowing ERK5 to auto-phosphorylate multiple sites in its C-terminal region, which can then regulate nuclear shuttling and gene transcription (3, 4). Noncanonical pathways (including cyclin-dependent kinases during mitosis and ERK1/2 during growth factor stimulation) also exist for phosphorylation of sites in the ERK5 tail (5-7). Although ERK5 has been demonstrated to directly phosphorylate transcription factors (8-10), the noncatalytic C-terminal tail of ERK5 can also interact with transcription factors and influence gene expression (4, 11, 12).

ERK5 can be activated in response to a range of mitogenic stimuli [e.g., growth factors, G protein-coupled receptor (GPCR) agonists, cytokines] and cellular stresses (e.g., hypoxia, shear stress) (13). Like most kinases including MAPK members, ERK5 function is assumed to be driven by its kinase activity. ERK5 deletion is embryonic lethal in mice and a variety of tissue- or development-stage restricted KOs have shown clear phenotypes, suggesting that the catalytic function and/or an aspect of the nonkinase domain(s) have key roles in development and mature organ function (14–18). The availability of the first ERK5 inhibitor XMD8-92 enabled the study of phenotypes resulting from direct kinase inhibition (19, 20). Effects of this inhibitor on cell proliferation were shown to be comparable to overexpression of a

dominant negative ERK5 mutant (20, 21) or to siRNA-mediated ERK5 knockdown (21, 22), implicating a key role of the kinase function. Multiple reports have shown promising and corroborating effects of ERK5 knockdown and pharmacological inhibition in controlling inflammation and tumor growth (20, 22–26).

Given the proposed therapeutic uses for ERK5 inhibitors, we set out to develop improved compounds with high selectivity and potency. With these ERK5 compounds, we show that first-generation ERK5 inhibitors actually derived the bulk of their biological activity from off-target activity on bromodomains (BRDs). Surprisingly, selective inhibition of the kinase activity alone had no effect on cellular immune response or proliferation, in contrast to whole ERK5 protein knockdown. The newly developed ERK selective inhibitors should prove useful in determining which phenotypes derive from catalytic activity and which derive from other functions of this multidomain kinase.

Results and Discussion

Inhibitors of ERK5. We synthesized derivatives of the benzopyrimidodiazepinone XMD8-92, a first-generation ERK5 kinase inhibitor (Fig. 1). Among these compounds were ATP-competitive inhibitors that potently inhibit ERK5 with IC₅₀ values ranging from 8 to 190 nM using the chemoproteomics platform KiNativ, which profiles global kinase inhibition in complex lysates (27, 28). At 1- μ M screening concentration, there was no significant inhibition of any off-target kinases among the greater than 100 kinases

Significance

Whole protein deletion and pharmacological inhibition are frequently used to functionally annotate enzymes. Each has limitations: whole protein deletion removes both enzymatic and nonenzymatic functions, and small molecule inhibitors can have unrecognized off-target activities. When both approaches agree, it's nearly incontrovertible support for protein function. Here we describe a counterexample. ERK5 knockdown and inhibition supported a role for this kinase in a number of biological processes. We show that previously reported ERK5 compounds inhibit bromodomain-containing proteins (BRDs) sufficiently to account for their phenotypic effects. We describe highly specific inhibitors of ERK5 that do not inhibit BRDs. With these, we show that cellular inflammation and proliferation are not dependent on ERK5 catalytic activity, thus making ERK5 unique among the MAP kinases.

Author contributions: E.C.K.L., J.I., and J.S.R. designed research; E.C.K.L. and C.M.A. performed research; Y.H., S.S., and B.L. contributed new reagents/analytic tools; E.C.K.L., C.M.A., T.K.N., and H.W. analyzed data; and E.C.K.L., H.W., J.I., Y.H., J.W.K., and J.S.R. wrote the paper.

Conflict of interest statement: E.C.K.L., C.M.A., T.K.N., H.W., Y.H., S.S., B.L., J.W.K., and J.S.R., employees of ActivX Biosciences, a wholly owned subsidiary of Kyorin Pharmaceutical Co., Ltd., and J.I., an employee of Kyorin Pharmaceutical Co., Ltd., have commercial interests in the development of ERK5 and BRD inhibitors.

This article is a PNAS Direct Submission.

Data deposition: The data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE86577).

¹To whom correspondence may be addressed. Email: emmel@activx.com or jonr@activx.com.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. 1073/pnas.1609019113/-/DCSupplemental.

Intra-Lysate cellular ERK5 Compound Structure ERK5 IC₅₀ (nM) IC₅₀ (nM) AX15836 8 9 но AX15839 170 430 AX15892 30 110 AX15910 20 17 XMD8-92 190 130

Fig. 1. Compound structures and potencies against ERK5 in cell lysate and in live cells treated with compound.

profiled in a single cellular lysate, indicating excellent specificity (Fig. S1).

The ERK5 inhibitors were also evaluated in an additional KiNativ experimental format wherein compound is incubated with live cells before washing, lysis, and analysis. Such experiments provide an indication of the cellular permeability of the compound and of intracellular target (and off-target) engagement. As seen in Fig. 1, intracellular ERK5 IC50 values were very similar to lysate ERK5 IC₅₀ values, demonstrating that the compounds effectively reached their intracellular target. The most selective ERK5 inhibitor AX15836 was also profiled using live cell KiNativ across several cell types, including peripheral blood mononuclear cells (PBMCs), endothelial cells, and oncogenic cell lines, and verified to maintain its intracellular potency (4-9 nM) across all cells tested.

The compounds were next tested for their ability to inhibit epidermal growth factor (EGF)-mediated auto-phosphorylation of endogenous ERK5 in HeLa cells (4). HeLa cells are commonly used to study ERK5 regulation in part due to the ability to clearly observe ERK5 activation resulting from triggers such as growth factors and mitosis (5, 29, 30). In this assay, activated ERK5 migrates more slowly than unactivated ERK5 on SDS/PAGE by virtue of the protein being phosphorylated. As seen in Fig. 2, when treated at 2 µM, approximately fivefold over the weakest intracellular ERK5 IC₅₀, all of the ERK5 inhibitors substantially blocked the formation of phosphorylated ERK5 on EGF stimulation. Because ERK5 is an intracellular target, this provided additional evidence, together with the KiNativ results, that the compounds were able to effectively engage their intracellular target.

Inhibitor Characterization in Cellular Inflammation Models. ERK5 has been recently studied as a target for mediating inflammation (23, 24, 26). We determined the activity of the ERK5 compounds in cellular assays of inflammatory response. To function in the recruitment of neutrophils and monocytes, the endothelial cell adhesion molecule E-selectin is rapidly synthesized in response to inflammatory stimulation (31). Primary human umbilical vein endothelial cells (HUVECs) were incubated with compounds before stimulation with the Toll-like receptor (TLR1/2) agonist Pam₃CSK₄. Up-regulation of cell-surface E-selectin was quantified by flow cytometry (Table 1). Similar to that reported by Wilhelmsen and colleagues (23), we found the ERK5 inhibitor XMD8-92 to inhibit up to 38% of the E-selectin expression. Likewise, two other ERK5 inhibitors, AX15839 and AX15910, were effective in reducing E-selectin. Surprisingly, two of the more potent ERK5 inhibitors (AX15836 and AX15892) were inactive in this assay, even at a concentration of compound at least 90-fold higher than the intracellular ERK5 IC_{50} (Fig. 1).

Given these results, it seemed likely that an additional activity was responsible for the efficacy of AX15839, AX15910, and XMD8-92. We therefore performed a more extensive KiNativ experiment to expand the kinase coverage to more than 200 kinases and furthermore increased the compound screening concentration to 10 µM. However, we still did not find any significant shared inhibition of off-target kinases among these three inhibitors (Fig. S2). XMD8-92 was derived from the polo-like kinase (PLK1) inhibitor BI-2536 (19, 20). Recently, BI-2536 (as well as a number of other kinase inhibitors) has been shown to inhibit the interaction between BRD and acetyl-lysine binding (32-34). BRDs are protein modules that bind to *ɛ-N*-acetylated lysine-containing sequences and modulate transcriptional processes. Members of the dual BRD-containing BET (bromo and extra terminal) proteins BRD2, BRD3, BRD4, and BRDT are targets of drugs currently pursued in oncology, neurological diseases, diabetes, atherosclerosis, and inflammation (35, 36). To determine whether XMD8-92 and other ERK5 kinase inhibitors can likewise inhibit BRDs, we screened the compounds against BRD4, the most wellstudied and key member of the BET protein family.

Table 2 shows the dissociation constants for compound binding to the first BRD of BRD4 [BRD4(1)]. Using the BROMOscan assay (DiscoveRx), two reference BRD inhibitors, JQ1 (37) and I-BET762 (38), exhibited potent BRD4 (1) K_d values. However, analysis of the ERK5 inhibitors using this method revealed a clear split. Compounds that were active in the E-selectin assay, AX15839, AX15910, and XMD8-92, potently interfered with the acetyl-lysine/ BRD4(1) interaction. These compounds thus represent dual inhibitors of ERK5 kinase and of BRD. In contrast, compounds that were potent on ERK5 but inactive in the E-selectin assay, AX15836 and AX15892, gave considerably higher BRD4 (1) dissociation constants, indicating loss of off-target BRD inhibition.

Knowing that the dual ERK5/BRD inhibitors were efficacious in the E-selectin HUVEC assay, whereas the ERK5-selective inhibitors had no effect (Table 1), we returned to that assay to measure the activity of the two BRD-selective reference inhibitors. Using 1 µM of I-BET762 and JQ1, we observed E-selectin reductions of 27% and 29%, respectively, confirming the notion that TLR1/2-induced E-selectin expression in endothelial cells







Table 1.	Surface E-selectin expression on endothelial cells
stimulate	d with TLR1/2 agonist Pam₃CSK₄

Condition	E-selectin expression (% of cell population)	Percent inhibition
DMSO	17.2	0
AX15836	18.5	0
AX15839	13.7	21
AX15892	18.1	0
AX15910	12.8	27
XMD8-92	10.9	38

HUVECs were pretreated with 10 μ M of compound before stimulation with 10 μ g/mL Pam₃CSK₄ for 4 h. E-selectin expression was detected and quantified by flow cytometry. Unstimulated cells expressed a baseline E-selectin expression of 0.6%. Shown are results from a representative experiment from at least two independent experiments.

could be reduced by BRD inhibition but not by ERK5 inhibition. Neither BRD inhibitor was active against ~100 kinases (including ERK5) when profiled at up to 10 μ M using KiNativ (Fig. S3).

We characterized the activities of several compounds from each classification type in additional cellular models of inflammation and found good consistency of response. For brevity, we show the results of three representative compounds: AX15836 as the ERK5-selective inhibitor, AX15839 as the dual ERK5/BRD inhibitor, and I-BET762 as the selective BRD inhibitor.

To determine whether the compounds could suppress inflammatory cytokine response, endothelial cells were pretreated with compound and stimulated with Pam₃CSK₄. Culture supernatants were subjected to immunoassay for cytokines IL-6 and IL-8. As seen in Table 3, compounds with BRD inhibition (selective and dual) suppressed IL-6 and IL-8; however, the ERK5specific inhibitor AX15836 was completely ineffective (EC₅₀ » 10 μ M), suggesting that it was the BRD inhibition component of the compounds that mediated cytokine reduction.

To determine whether the lack of ERK5-specific effect was limited to a certain cell type and agonist, we repeated the experiment using a normal human bronchial epithelial cell line, BEAS-2B. ERK5 has been identified to be part of an IL-17-mediated signaling cascade that drives keratinocyte proliferation and tumorigenesis (39). IL-17A is also overexpressed in conditions of chronic inflammation such as asthma and is thought to mediate airway neutrophilia through the induction of additional cytokines from target cells (40-42). After preincubation with compound, BEAS-2B cells were stimulated with the proinflammatory cytokine IL-17A. IL-6 and IL-8 cytokine release from the bronchial epithelial cells were measured by immunoassay (Table 4). Again, the ERK5-selective compound AX15836 had no effect on these induced cytokines. In contrast, inhibitors with BRD inhibition activity suppressed inflammatory cytokine response to IL-17A in this cell type.

Cellular function of a protein is often studied by reducing its expression via RNA interference. The interpretability of removing the entire protein is typically justified when small molecule inhibitors can demonstrate the same phenotype. In multiple studies (20, 22-25), ERK5 kinase inhibition using XMD8-92 has been used in parallel to siRNA-mediated knockdown of ERK5 to show two lines of supporting evidence for ERK5's role. Given the lack of cellular effect by selective ERK5 kinase inhibitors, we used siRNA to deplete ERK5 in the HUVECs and BEAS-2B cells to evaluate the role of ERK5 presence. Cells were transfected with siRNA to significantly reduce ERK5 protein expression, as confirmed by Western blots on days 2 and 4 after transfection (Fig. 3 A and B). On day 2 after transfection, cells were stimulated with the respective agonists, and the culture supernatant was collected 2 d later (day 4 after transfection) for cytokine analysis. Indeed, depletion of ERK5 protein resulted in a reduction in IL-6 and IL-8 in both endothelial and epithelial cells (Fig. 3 C and D). These data show that the entire ERK5 protein is necessary for modulating inflammatory response. The contrasting lack of effect by specific small molecule-mediated inhibition of ERK5 kinase activity suggests that a noncatalytic function of ERK5 plays a more important role.

We searched for an antiinflammatory effect of AX15836 in additional cellular models of innate and adaptive immunity from both murine and human sources, as listed in Table S1. Inhibition of BRD/acetyl-lysine binding with either JQ1 or I-BET762 resulted in efficacy in several models. In contrast, the ERK5-only inhibitor AX15836 was ineffective against all models tested. We therefore conclude that ERK5 kinase activity does not have a role in cellular immune response.

Characterization of Inhibitors in Cancer Cell Proliferation and Viability. ERK5 and BRDs have been separately studied as targets for oncology. ERK5 was proposed to control multiple processes important for tumorigenesis, including cellular proliferation, survival, invasion, and angiogenesis (43). To reevaluate the role of ERK5 kinase inhibition in cancer cell proliferation, we tested our panel of inhibitors for effects on two cancer cell lines in which ERK5 has been characterized to mediate cell growth and survival. MM.1S multiple myeloma cells express ERK5, which can be activated by IL-6, a growth factor for this cancer type (44). IL-6-induced ERK5 activation was prevented by ERK5 inhibitors (specific ERK5 inhibitor AX15836 and dual ERK5/BRD inhibitor AX15839) (Fig. 4A), confirming target engagement. Overexpression of a dominant negative form of ERK5 was reported to block IL-6-induced MM.1S proliferation (44). We compared IL-6-dependent proliferation in the presence or absence of the highly specific ERK5 inhibitor AX15836 (Fig. 4B), but did not observe a significant effect on cell growth. As such, it seems likely that the reported antiproliferation activity of overexpressing the dominant negative ERK5 mutant in MM.1S cells is the result of non-kinase-related or non-ERK5-related activity of that construct.

Table 2	Inhibitor	characteristics	and	classification
	minipitor	characteristics	anu	classification

Compound	ERK5 IC ₅₀ (nM)*	BRD4 (1) K_{d} (nM) [†]	Ratio of ERK5 IC ₅₀ :BRD4 (1) K _d	Inhibitor classification
AX15836	8	3,600	0.002	ERK5
AX15892	30	610	0.049	ERK5
AX15839	170	130	1.3	Dual
AX15910	20	22	0.9	Dual
XMD8-92	190	170	1.1	Dual
I-BET762	>10,000	31	>320	BRD
JQ1	>10,000	6	>1,670	BRD

*ERK5 IC50 value determined using KiNativ.

[†]BRD4 (1) K_d value determined at DiscoveRx.

Table 3. EC_{50} values of compounds in reducing cytokines IL-6 and IL-8 produced by endothelial cells stimulated with TLR1/2 agonist Pam₃CSK₄

Compound	Inhibitor classification	EC ₅₀ (µM) of cytokine reduction		
		IL-6	IL-8	
AX15836	ERK5	>>10	>>10	
AX15839	Dual	1.73	1.79	
I-BET762	BRD	0.15	0.12	

HUVECs were pretreated with compound before stimulation with 10 μ g/mL Pam₃CSK₄ for 48 h. Culture supernatants were tested for cytokines by immunoassay. Shown are results from a representative experiment from at least two independent experiments.

We likewise evaluated these inhibitors on the proliferation of the acute myeloid leukemia cell line MV4-11, which expresses the activating internal tandem duplication (ITD) mutation of FLT3 (FLT3-ITD). This driver mutation was reported to constitutively activate ERK5, and inhibition of the upstream kinase MEK5 led to reduced cell proliferation and viability (45). As previously noted in the literature (34), we found reference BRD inhibitors to be effective in this model, with EC_{50} values of 60 ± 10 and 170 ± 10 nM for JQ1 and I-BET762, respectively (mean \pm SD of three experiments). Viability EC₅₀s of the dual ERK5/BRD inhibitors (AX15839, AX15910, and XMD8-92) were less potent and ranged from 1.10 ± 0.25 to $3.28 \pm 1.14 \mu$ M. Again, however, we observed no effect with the selective ERK5 compounds AX15836 and AX15892 (EC₅₀s > 15 μ M). Our studies thus demonstrate that highly specific pharmacological inhibition of ERK5 catalytic activity had no effect on cell growth or viability in cancer cell lines previously characterized to be regulated by this kinase. Although xenograft studies might further delineate a more complex role of ERK5 kinase activity, pharmacokinetic characterization of AX15836 (Table S2) did not indicate it to be optimal for in vivo dosing.

Transcriptome Analysis of Cellular ERK5 Kinase Inhibition. We sought to analyze the effects of selective ERK5 inhibition in comparison to BRD inhibition (either dual ERK/BRD or BRD-only) on genome-wide gene expression. Two cellular models with reported ERK5-regulated signaling were used: Pam₃CSK₄-stimulated HUVECs (23, 24) as a model of inflammation, and EGF-stimulated HeLa cells (5, 20, 29) as an established cell model of ERK5 regulation. Cells were preincubated with DMSO vehicle, AX15836 (ERK5 inhibitor), AX15839 (dual ERK5/BRD inhibitor), or I-BET762 (BRD inhibitor) and then stimulated with agonist. Cellular responses were verified by immunoassays and Western blots using replicate wells in the same experiment.

Table 4. EC_{50} values of compounds in reducing cytokines IL-6 and IL-8 produced by bronchial epithelial cells stimulated with IL-17A

Compound	Inhibitor classification	EC_{50} (µM) of cytokine reduction		
		IL-6	IL-8	
AX15836	ERK5	>>10	>>10	
AX15839	Dual	1.13	1.07	
I-BET762	BRD	0.16	0.07	

BEAS-2B cells were pretreated with compound before stimulation with 50 ng/mL IL-17A for 48 h. Culture supernatants were tested for cytokines by immunoassay. Shown are results from a representative experiment from at least two independent experiments.



Fig. 3. ERK5 knockdown suppresses inflammatory cytokine response. HUVEC (A) and BEAS-2B (B) cells were transiently transfected with mock treatment, scrambled siRNA control (siScr), or siRNA against ERK5 (siERK5). Expression of ERK5 and β -actin was monitored by Western blot on day 2 (addition of Pam3CysK4 or IL-17) and day 4 (collection of culture supernatant for cytokine analyses). Immunoassay of IL-6 and IL-8 from treated HUVEC (C) and BEAS-2B (D) cells indicates significant suppression of inflammatory cytokines when ERK5 is depleted. Figures are representative experiments from two independent experiments.

RNA sequencing (RNA-Seq) of biological triplicates detected at least one transcript for 18,925 genes in HUVEC samples and 17,266 genes in HeLa samples. In both cell types, samples treated with AX15836 showed very few genes to be differentially expressed (Fig. 5A). The total number of genes using the default cutoff (adjusted $P \le 0.1$) for plotting log-intensity ratios (M-values) versus log-intensity averages (A-values) (MA plot) was seven in HUVEC samples and two in HeLa samples. Moreover, the observed maximal fold-changes in expression compared with the DMSO control samples were modest: below 1.6 and 2 for HUVEC and HeLa samples, respectively. Principal component analysis of all samples further confirmed the lack of differential gene expression in samples treated with the ERK5-only inhibitor AX15836. Conversely, cells treated with the dual ERK5/BRD inhibitor AX15839 and those treated with the BRD inhibitor I-BET762 showed a large number of differentially expressed genes (Fig. 5A). The correlation of fold-changes in expression of those genes is shown in Fig. 5B. The majority of the genes showed comparable expression patterns in that they were expressed at either higher or lower levels in each of the treated



Fig. 4. Multiple myeloma (MM).1S cell growth is not affected by selective ERK5 inhibition. (A) IL-6 activates ERK5 in MM.1S cells, as shown by the appearance of a mobility retarded, auto-phosphorylated ERK5 band (upper arrow) on Western blot. Inhibitors (2 μ M) with ERK5 inhibitory activity (AX15836 and AX15839) prevented the induction of p-ERK5. (B) After 3 d of incubation, viable MM.1S cells were quantified in an assay measuring ATP content and expressed as relative luminescence. The ERK5-selective inhibitor AX15836 (1.67 μ M) did not significantly reduce IL-6-dependent proliferation relative to the DMSO + IL-6 control. Data graphed in *B* are the mean \pm SD of three independent experiments.



Fig. 5. Differential gene expression in HUVECs and HeLa cells treated with AX15836, AX15839, and I-BET762 indicates lack of effect by selective ERK5 inhibition. (*A*) MA plots for HUVECs (*Left*) and HeLa cells (*Right*) treated with AX15836 (836; *Top*), AX15839 (839; *Middle*), and I-BET762 (iBET; *Bottom*). Differentially expressed genes with an adjusted *P* value (DESeq2) of 0.1 or less are shown in red. (*B*) Correlation of gene expression profiles in HUVECs (*Top*) and HeLa cells (*Bottom*) treated with AX15839 and I-BET762. The log2

samples compared with controls, confirming a shared regulatory mechanism between AX15839 and I-BET762.

Looking at individual genes of interest, AX15839 and I-BET762 significantly reduced Pam₃CSK₄-stimulated HUVEC gene expression of IL6 [log2 fold-change (FC) -0.72, P < 0.01 and log2 FC -1.32, P < 0.001, respectively] and CXCL8 (log2 FC -0.73, P < 0.001and log2 FC -1.42, P < 0.001, respectively), consistent with the observed reductions in IL-6 and IL-8 proteins. SELE (E-selectin) transcripts were also reduced by these compounds (log2 FC -0.47, P < 0.001 and log2 FC -0.69, P < 0.001, respectively), consistent with the observed reduction in protein expression by flow cytometry. Additionally, both compounds with BRD inhibition (AX15839 and I-BET762) significantly suppressed transcription of other genes involved in inflammation, such as IL7R (IL-7 receptor) (log2 FC -1.84, P < 0.001 and log2 FC -2.38, P < 0.001, respectively), *PTGS2* (COX-2) (log2 FC -1.11, *P* < 0.001 and log2 FC -1.65, P < 0.001, respectively), and CSF2 (GM-CSF) (log2 FC -1.02, P <0.001 and log2 FC -1.60, P < 0.001, respectively), whereas inhibition of ERK5 kinase alone (AX15836) had no effect. Thus, pharmacological inhibition of ERK5 kinase activity was not able to reduce inflammatory gene expression in endothelial cells, further supporting the concept that the previously observed efficacy in first-generation ERK5 inhibitors was due to an unrecognized inhibition of BRD/acetyl-lysine interaction.

We had shown that AX15836 could clearly inhibit the EGFstimulated, phosphorylated form of ERK5 in HeLa cells, a frequently studied cell model of ERK5 regulation. We thus postulated that if the subsequent transcriptional effects of inhibiting ERK5 catalytic function could be seen, it would be in these cells. However, we found no significant impact of AX15836 treatment. In contrast, the four genes most highly suppressed by both AX15839 and I-BET762 were as follows: HAS2 (hyaluronan synthase 2) (log2 FC -2.53, P < 0.001 and log2 FC -3.50, P < 0.001, respectively), *IL7R* (log2 FC -2.08, P < 0.001 and log2 FC -2.93, P < 0.001, respectively), CXCL8 (log2 FC -1.90, P < 0.001 and log2 FC -2.14, P < 0.001, respectively), and IL6 (log2 FC -1.73, P <0.001 and log2 FC -2.69, P < 0.001, respectively). The transcription of both HAS2 and IL7R have recently been reported to be potently down-regulated by BET BRD inhibition in tumor cell lines and are thought to play key roles in cell growth and survival (46, 47). Consistent with previous observations that BRD inhibitors have differential effects on MYC, we also did not observe a reduction of MYC in HeLa cells (48); however, transcripts for cytokines IL-6 and IL-8, known to be increased in HeLa cells by EGF-mediated signaling (49), were suppressed by BRD inhibition. Our transcriptome profiling indicates that pharmacological inhibition of ERK5 kinase activity has no significant impact on gene transcription in two cell models, suggesting that phenotypes observed from genetic ablation of ERK5 result from kinase signaling-independent mechanisms. Future experiments comparing transcriptome effects of kinase inhibition by small molecules to genetic models of catalytically inactive or auto-phosphorylation site mutant ERK5 could be highly informative.

Conclusion

The biological function of ERK5 has been studied by a wide variety of experimental techniques. Genetic approaches in intact animals established a role for ERK5 in vascular and neuronal function. Depletion by siRNA in cell models implicated ERK5 in inflammatory and oncogenic pathways, and overexpression of a kinase-dead ERK5 mutant blocked numerous signaling events.

FC for compound-treated samples compared with the DMSO control samples are plotted for each gene. Outliers are highlighted in red and include those differentially expressed genes (at least a $1.5\times$ fold-change and an adjusted *P* value below 0.05 in one of the samples) with a residual outside of three times the SD of all residuals.

Taken together, these experiments were useful to indicate the range of biological processes that ERK5 could influence. Because ERK5 is a kinase that has been demonstrated to phosphorylate transcription factors, the genetic phenotypes have been interpreted as being the result of removing the catalytic activity. However, the selective ERK5 inhibitors described here lack the antiinflammatory and antiproliferative effects induced by genetic manipulation of ERK5. The simplest explanation for this is that the immune and proliferation effects seen in ERK5 genetic models are due to ablation of nonkinase functions of ERK5. Interestingly, essential noncatalytic functions such as protein scaffolding, allosteric regulation of other enzymes, and DNA binding can be found in all seven major kinase groups (50). Separately, we demonstrate that previously reported ERK5 inhibitors, exemplified by XMD8-92, have off-target activity on an unrelated class of proteins, the BRDs. Our experiments show that BRD inhibition is sufficient to account for the antiinflammatory and antiproliferative cellular responses previously ascribed to ERK5 inhibition via XMD8-92. It appears to be pure happenstance that there is overlap between the phenotypes of BRD inhibition and ERK5 depletion/deletion.

- 1. Morrison DK (2012) MAP kinase pathways. Cold Spring Harb Perspect Biol 4(11): a011254.
- Mody N, Campbell DG, Morrice N, Peggie M, Cohen P (2003) An analysis of the phosphorylation and activation of extracellular-signal-regulated protein kinase 5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in vitro. *Biochem J* 372(Pt 2):567–575.
- Kondoh K, Terasawa K, Morimoto H, Nishida E (2006) Regulation of nuclear translocation of extracellular signal-regulated kinase 5 by active nuclear import and export mechanisms. Mol Cell Biol 26(5):1679–1690.
- Morimoto H, Kondoh K, Nishimoto S, Terasawa K, Nishida E (2007) Activation of a C-terminal transcriptional activation domain of ERK5 by autophosphorylation. J Biol Chem 282(49):35449–35456.
- Díaz-Rodríguez E, Pandiella A (2010) Multisite phosphorylation of Erk5 in mitosis. J Cell Sci 123(Pt 18):3146–3156.
- Iñesta-Vaquera FA, et al. (2010) Alternative ERK5 regulation by phosphorylation during the cell cycle. Cell Signal 22(12):1829–1837.
- Honda T, et al. (2015) Phosphorylation of ERK5 on Thr732 is associated with ERK5 nuclear localization and ERK5-dependent transcription. *PLoS One* 10(2):e0117914.
- English JM, Pearson G, Baer R, Cobb MH (1998) Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. J Biol Chem 273(7):3854–3860.
- Kamakura S, Moriguchi T, Nishida E (1999) Activation of the protein kinase ERK5/ BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 274(37):26563–26571.
- Kato Y, et al. (1997) BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. *EMBO J* 16(23):7054–7066.
- Kasler HG, Victoria J, Duramad O, Winoto A (2000) ERK5 is a novel type of mitogenactivated protein kinase containing a transcriptional activation domain. *Mol Cell Biol* 20(22):8382–8389.
- Sohn SJ, Li D, Lee LK, Winoto A (2005) Transcriptional regulation of tissue-specific genes by the ERK5 mitogen-activated protein kinase. *Mol Cell Biol* 25(19):8553–8566.
- Nithianandarajah-Jones GN, Wilm B, Goldring CEP, Müller J, Cross MJ (2012) ERK5: Structure, regulation and function. Cell Signal 24(11):2187–2196.
- Yan L, et al. (2003) Knockout of ERK5 causes multiple defects in placental and embryonic development. BMC Dev Biol 3(1):11.
- Regan CP, et al. (2002) Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci USA 99(14):9248–9253.
- Pan Y-W, et al. (2012) Inducible and conditional deletion of extracellular signal-regulated kinase 5 disrupts adult hippocampal neurogenesis. J Biol Chem 287(28):23306–23317.
- Hayashi M, et al. (2004) Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest 113(8):1138–1148.
- Angulo-Ibáñez M, et al. (2015) Erk5 contributes to maintaining the balance of cellular nucleotide levels and erythropoiesis. *Cell Cycle* 14(24):3864–3876.
- Deng X, et al. (2011) Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1. ACS Med Chem Lett 2(3):195–200.
- Yang Q, et al. (2010) Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. *Cancer Cell* 18(3):258–267.
- Bera A, et al. (2014) A positive feedback loop involving Erk5 and Akt turns on mesangial cell proliferation in response to PDGF. Am J Physiol Cell Physiol 306(11):C1089–C1100.
- Rovida E, et al. (2015) The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Gut 64(9):1454–1465.
- Wilhelmsen K, Mesa KR, Lucero J, Xu F, Hellman J (2012) ERK5 protein promotes, whereas MEK1 protein differentially regulates, the Toll-like receptor 2 proteindependent activation of human endothelial cells and monocytes. *J Biol Chem* 287(32): 26478–26494.
- Wilhelmsen K, et al. (2015) Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation. Sci Signal 8(391):ra86–ra86.
- Song C, et al. (2015) Inhibition of BMK1 pathway suppresses cancer stem cells through BNIP3 and BNIP3L. Oncotarget 6(32):33279–33289.

Our findings show that ERK5 is a highly unusual MAP kinase. Like the other MAPK members, ERK5 is involved in a number of central biological pathways. In stark contrast, however, the kinase activity of ERK5 appears to be unnecessary for many of its most widely studied functions.

Materials and Methods

For determination of native kinase engagement, compounds were profiled in cell lysates or live cells using the KiNativ chemoproteomics platform (ActivX Biosciences) (27, 28, 51). For flow cytometry, ERK5 auto-phosphorylation, immunoanalyses, and RNA-Seq, cells were treated for 1 h with compounds before agonist stimulation, followed by standard protocols. Experimental details and compound synthetic schemes are provided in *SI Materials and Methods*. In vivo study protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Agilux Laboratories.

ACKNOWLEDGMENTS. We thank our colleague and friend, the late Dr. Kevin Shreder, for invaluable contributions. We thank Kai Nakamura, Lan Pham, Ray Li, and Julia Ayers for chemical syntheses and Maria Sykes and Heidi Brown for assistance on live cell KiNativ.

- Finegan KG, et al. (2015) ERK5 is a critical mediator of inflammation-driven cancer. Cancer Res 75(4):742–753.
- Patricelli MP, et al. (2011) In situ kinase profiling reveals functionally relevant properties of native kinases. *Chem Biol* 18(6):699–710.
- Patricelli MP, et al. (2007) Functional interrogation of the kinome using nucleotide acyl phosphates. *Biochemistry* 46(2):350–358.
- Kato Y, et al. (1998) Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395(6703):713–716.
- Cude K, et al. (2007) Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J Cell Biol 177(2):253–264.
- Peebles RS, Jr, Bochner BS, Schleimer RP (1995) Pharmacologic regulation of adhesion molecule function and expression. *Inflammation: Mediators and Pathways*, eds Ruffolo, Jr RR, Hollinger MA (CRC Press, New York), pp 29–96.
- Martin MP, Olesen SH, Georg GI, Schönbrunn E (2013) Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem Biol 8(11):2360–2365.
- Ember SWJ, et al. (2014) Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem Biol 9(5):1160–1171.
- Ciceri P, et al. (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 10(4):305–312.
- Filippakopoulos P, Knapp S (2014) Targeting bromodomains: Epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13(5):337–356.
- Padmanabhan B, Mathur S, Manjula R, Tripathi S (2016) Bromodomain and extraterminal (BET) family proteins: New therapeutic targets in major diseases. J Biosci 41(2):295–311.
- Filippakopoulos P, et al. (2010) Selective inhibition of BET bromodomains. Nature 468(7327):1067–1073.
- Mirguet O, et al. (2013) Discovery of epigenetic regulator I-BET762: Lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J Med Chem 56(19):7501–7515.
 Wu L, et al. (2015) A novel IL-17 signaling pathway controlling keratinocyte pro-
- We L, et al. (2015) A hoven le 17 signaling patiway containing kelanotyce patients.
 Iferation and tumorigenesis via the TRAF4-ERKS axis. J Exp Med 212(10):1571–1587.
 Laan M, Lötvall J, Chung KF, Lindén A (2001) IL-17-induced cytokine release in human
- Laan M, Lotvall J, Chung KP, Linder A (2001) IL-17-Induced Cytokine release in human bronchial epithelial cells in vitro: Role of mitogen-activated protein (MAP) kinases. Br J Pharmacol 133(1):200–206.
- Chesné J, et al. (2014) IL-17 in severe asthma. Where do we stand? Am J Respir Crit Care Med 190(10):1094–1101.
- Kawaguchi M, et al. (2001) Modulation of bronchial epithelial cells by IL-17. J Allergy Clin Immunol 108(5):804–809.
- Lochhead PA, Gilley R, Cook SJ (2012) ERK5 and its role in tumour development. Biochem Soc Trans 40(1):251–256.
- 44. Carvajal-Vergara X, et al. (2005) Multifunctional role of Erk5 in multiple myeloma. Blood 105(11):4492–4499.
- Razumovskaya E, Sun J, Rönnstrand L (2011) Inhibition of MEK5 by BIX02188 induces apoptosis in cells expressing the oncogenic mutant FLT3-ITD. *Biochem Biophys Res Commun* 412(2):307–312.
- Lockwood WW, Zejnullahu K, Bradner JE, Varmus H (2012) Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci USA 109(47):19408–19413.
- Ott CJ, et al. (2012) BET bromodomain inhibition targets both c-Myc and IL7R in highrisk acute lymphoblastic leukemia. *Blood* 120(14):2843–2852.
- Fowler T, et al. (2014) Regulation of MYC expression and differential JQ1 sensitivity in cancer cells. *PLoS One* 9(1):e87003.
- Amit I, et al. (2007) A module of negative feedback regulators defines growth factor signaling. Nat Genet 39(4):503–512.
- Rauch J, Volinsky N, Romano D, Kolch W (2011) The secret life of kinases: Functions beyond catalysis. Cell Commun Signal 9(1):23.
- Okerberg ES, et al. (2014) Monitoring native p38α:MK2/3 complexes via trans delivery of an ATP acyl phosphate probe. J Am Chem Soc 136(12):4664–4669.